Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Sep;74(3):736–744. doi: 10.1172/JCI111489

Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.

J J Sixma, K S Sakariassen, H V Stel, W P Houdijk, D W In der Maur, R J Hamer, P G de Groot, J A van Mourik
PMCID: PMC425227  PMID: 6332119

Abstract

We have identified two functional domains on the von Willebrand factor (VWF) moiety of the Factor VIII-von Willebrand factor complex (FVIII-VWF), one interacting with blood platelets, and one interacting with vessel wall collagens, by means of two monoclonal antibodies directed against the VWF molecule, CLB-RAg 35 and CLB-RAg 201. The monoclonal antibody CLB-RAg 35 inhibited virtually all platelet adherence to artery subendothelium and to purified vessel wall collagen type III, at relatively high wall shear rates. CLB-RAg 35 also inhibited the ristocetin-induced platelet aggregation and the binding of FVIII-VWF to the platelet in the presence of ristocetin but did not affect the binding of FVIII-VWF to collagen. The monoclonal antibody CLB-RAg 201 inhibited the binding of FVIII-VWF to purified vessel wall collagen type I and III and all platelet adherence to collagen type III and the platelet adherence to subendothelium that was mediated by FVIII-VWF in plasma. The two functional domains on FVIII-VWF that were recognized by CLB-RAg 35 and CLB-RAg 201 were identified by means of immunoprecipitation studies of trypsin-digested FVIII-VWF. The domains resided on different polypeptide fragments, with a Mr of 48,000 for the collagen binding domain and a Mr of 116,000 for the platelet binding domain. The 116,000-mol wt fragment consisted of subunits of 52,000/56,000 mol wt and 14,000 mol wt after reduction. The 52,000/56,000-mol wt subunits possessed the epitope for CLB-RAg 35.

Full text

PDF
736

Images in this article

741Image
on p.741
741Image
on p.741
741Image
on p.741
742Image
on p.742
742Image
on p.742

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumgartner H. R. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res. 1973 Mar;5(2):167–179. doi: 10.1016/0026-2862(73)90069-1. [DOI] [PubMed] [Google Scholar]
  2. Baumgartner H. R., Tschopp T. B., Meyer D. Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Br J Haematol. 1980 Jan;44(1):127–139. doi: 10.1111/j.1365-2141.1980.tb01190.x. [DOI] [PubMed] [Google Scholar]
  3. Borst J., Prendiville M. A., Terhorst C. Complexity of the human T lymphocyte-specific cell surface antigen T3. J Immunol. 1982 Apr;128(4):1560–1565. [PubMed] [Google Scholar]
  4. ChandraRajan J. Separation of type III collagen from type I collagen and pepsin by differential denaturation and renaturation. Biochem Biophys Res Commun. 1978 Jul 14;83(1):180–186. doi: 10.1016/0006-291x(78)90414-x. [DOI] [PubMed] [Google Scholar]
  5. Chung E., Miller E. J. Collagen polymorphism: characterization of molecules with the chain composition (alpha 1 (3)03 in human tissues. Science. 1974 Mar;183(130):1200–1201. doi: 10.1126/science.183.4130.1200. [DOI] [PubMed] [Google Scholar]
  6. Doucet-de Bruïne M. H., Sixma J. J., Over J., Beeser-Visser N. H. Heterogeneity of human factor VIII. II. Characterization of forms of factor VIII binding to platelets in the presence of ristocetin. J Lab Clin Med. 1978 Jul;92(1):96–107. [PubMed] [Google Scholar]
  7. Guisasola J. A., Cockburn C. G., Hardisty R. M. Plasmin digestion of factor VIII: characterization of the breakdown products with respect to antigenicity and von Willebrand activity. Thromb Haemost. 1978 Oct 31;40(2):302–315. [PubMed] [Google Scholar]
  8. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  9. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  10. Legrand Y. J., Rodriguez-Zeballos A., Kartalis G., Fauvel F., Caen J. P. Adsorption of factor VIII antigen-activity complex by collagen. Thromb Res. 1978 Nov;13(5):909–911. doi: 10.1016/0049-3848(78)90196-2. [DOI] [PubMed] [Google Scholar]
  11. Martin S. E., Marder V. J., Francis C. W., Loftus L. S., Barlow G. H. Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood. 1980 May;55(5):848–858. [PubMed] [Google Scholar]
  12. Meyer D., Obert B., Pietu G., Lavergne J. M., Zimmerman T. S. Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease. J Lab Clin Med. 1980 Apr;95(4):590–602. [PubMed] [Google Scholar]
  13. Over J., Bouma B. N., van Mourik J. A., Sixma J. J., Vlooswijk R., Bakker-Woudenberg I. Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med. 1978 Jan;91(1):32–46. [PubMed] [Google Scholar]
  14. Over J., Sixma J. J., Bruïne M. H., Trieschnigg M. C., Vlooswijk R. A., Beeser-Visser N. H., Bouma B. N. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J Clin Invest. 1978 Aug;62(2):223–234. doi: 10.1172/JCI109120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pasquini R., Hershgold E. J. Effects of plasmin on human factor VIII (AHF). Blood. 1973 Jan;41(1):105–111. [PubMed] [Google Scholar]
  16. Phillips D. R., Agin P. P. Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis. J Biol Chem. 1977 Mar 25;252(6):2121–2126. [PubMed] [Google Scholar]
  17. Pierschbacher M. D., Hayman E. G., Ruoslahti E. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell. 1981 Oct;26(2 Pt 2):259–267. doi: 10.1016/0092-8674(81)90308-1. [DOI] [PubMed] [Google Scholar]
  18. Ploplis V. A., Cummings H. S., Castellino F. J. Monoclonal antibodies to discrete regions of human Glu1-plasminogen. Biochemistry. 1982 Nov 9;21(23):5891–5897. doi: 10.1021/bi00266a025. [DOI] [PubMed] [Google Scholar]
  19. Ruggeri Z. M., Zimmerman T. S. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980 Jun;65(6):1318–1325. doi: 10.1172/JCI109795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sakariassen K. S., Bolhuis P. A., Sixma J. J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature. 1979 Jun 14;279(5714):636–638. doi: 10.1038/279636a0. [DOI] [PubMed] [Google Scholar]
  21. Sakariassen K. S., Bolhuis P. A., Sixma J. J. Platelet adherence to subendothelium of human arteries in pulsatile and steady flow. 1980 Aug 15-Sep 1Thromb Res. 19(4-5):547–559. doi: 10.1016/0049-3848(80)90027-4. [DOI] [PubMed] [Google Scholar]
  22. Santoro S. A. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res. 1981 Mar 15;21(6):689–691. doi: 10.1016/0049-3848(81)90272-3. [DOI] [PubMed] [Google Scholar]
  23. Sixma J. J., Sakariassen K. S., Beeser-Visser N. H., Ottenhof-Rovers M., Bolhuis P. A. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood. 1984 Jan;63(1):128–139. [PubMed] [Google Scholar]
  24. Sixma J. J., Wester J. The hemostatic plug. Semin Hematol. 1977 Jul;14(3):265–299. [PubMed] [Google Scholar]
  25. Stel H. V., Sakariassen K. S., Scholte B. J., Veerman E. C., van der Kwast T. H., de Groot P. G., Sixma J. J., van Mourik J. A. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood. 1984 Jun;63(6):1408–1415. [PubMed] [Google Scholar]
  26. Stel H. V., Veerman E. C., Huisman J. G., Janssen M. C., van Mourik J. A. A rapid one-step immunoradiometric assay for factor VIII-procoagulant antigen utilizing monoclonal antibodies. Thromb Haemost. 1983 Dec 30;50(4):860–863. [PubMed] [Google Scholar]
  27. Sussman I. I., Rand J. H. Subendothelial deposition of von Willebrand's factor requires the presence of endothelial cells. J Lab Clin Med. 1982 Oct;100(4):526–532. [PubMed] [Google Scholar]
  28. Tschopp T. B., Baumgartner H. R. Platelet adhesion and mural platelet thrombus formation on aortic subendothelium of rats, rabbits, and guinea pigs correlate negatively with the vascular PGI2 production. J Lab Clin Med. 1981 Sep;98(3):402–411. [PubMed] [Google Scholar]
  29. Weiss H. J., Turitto V. T., Baumgartner H. R. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate--dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med. 1978 Nov;92(5):750–764. [PubMed] [Google Scholar]
  30. Zimmerman T. S., Roberts J., Edgington T. S. Factor-VIII-related antigen: multiple molecular forms in human plasma. Proc Natl Acad Sci U S A. 1975 Dec;72(12):5121–5125. doi: 10.1073/pnas.72.12.5121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. van Mourik J. A., Mochtar I. A. Purification of human antihemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta. 1970 Dec 22;221(3):677–679. doi: 10.1016/0005-2795(70)90247-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES